Moreover, due to lowered cost and routine application of next-generation sequencing (NGS) testing in the clinical setting, our knowledge of tumours that harbour NTRK fusions, targetable with TRK inhibitors are expanding, improving our understanding of rare tumours and enabling precision-based therapeutic management of clinically challenging tumours (10–12). Here, NTRK1 is linked to neoplasm.